Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta-Analysis

Rafail A. Kotronias, MBChB, MSc; Chun Shing Kwok, MBBS, MSc; Sudhakar George, MBChB; Davide Capodanno, MD, PhD; Peter F. Ludman, MD, FRCP, FESC; Jonathan N. Townend, MD, FRCP; Sagar N. Doshi, MBChB, MD, FRCP; Sab S. Khogali, MBChB, MD, FRCP; Philippe Généreux, MD; Howard C. Herrmann, MD, FACC, MScAI; Mamas A. Mamas, MBMBCh, DPhil; Rodrigo Bagur, MD, PhD, FAHA

Background—Recent recommendations suggest that in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation and coexistent significant coronary artery disease, the latter should be treated before the index procedure; however, the evidence basis for such an approach remains limited. We performed a systematic review and meta-analysis to study the clinical outcomes of patients with coronary artery disease who did or did not undergo revascularization prior to transcatheter aortic valve implantation.

Methods and Results—We conducted a search of Medline and Embase to identify studies evaluating patients who underwent transcatheter aortic valve implantation with or without percutaneous coronary intervention. Random-effects meta-analyses with the inverse variance method were used to estimate the rate and risk of adverse outcomes. Nine studies involving 3858 participants were included in the meta-analysis. Patients who underwent revascularization with percutaneous coronary intervention had a higher rate of major vascular complications (odd ratio [OR]: 1.86; 95% confidence interval [CI], 1.33–2.60; P=0.0003) and higher 30-day mortality (OR: 1.42; 95% CI, 1.08–1.87; P=0.01). There were no differences in effect estimates for 30-day cardiovascular mortality (OR: 1.03; 95% CI, 0.35–2.99), myocardial infarction (OR: 0.86; 95% CI, 0.14–5.28), acute kidney injury (OR: 0.89; 95% CI, 0.42–1.88), stroke (OR: 1.07; 95% CI, 0.38–2.97), or 1-year mortality (OR: 1.05; 95% CI, 0.71–1.56). The timing of percutaneous coronary intervention (same setting versus a priori) did not negatively influence outcomes.

Conclusions—Our analysis suggests that revascularization before transcatheter aortic valve implantation confers no clinical advantage with respect to several patient-important clinical outcomes and may be associated with an increased risk of major vascular complications and 30-day mortality. In the absence of definitive evidence, careful evaluation of patients on an individual basis is of paramount importance to identify patients who might benefit from elective revascularization. (J Am Heart Assoc. 2017;6:e005960. DOI: 10.1161/JAHA.117.005960.)

Key Words: coronary artery disease • percutaneous coronary intervention • transcatheter aortic valve implantation

Coronary artery disease (CAD) often coexists in patients with severe aortic stenosis (AS),1,2 and current American and European guidelines recommend combined coronary artery bypass grafting at the time of surgical aortic valve replacement.3,4 Concomitant coronary artery bypass grafting and surgical aortic valve replacement are...
Revascularization in TAVI  Kotronias et al

Clinical Perspective

What Is New?

- The prevalence of coexisting coronary artery disease in populations undergoing transcatheter aortic valve implantation averaged 70%.
- Anatomically significant coronary artery disease was inconsistently defined and varied from at least ≥50% to >90% diameter stenosis.
- None of the available data reported on the use of functional assessment for coronary artery disease significance.
- Major vascular complications and 30-day mortality may be increased among patients undergoing percutaneous coronary intervention revascularization before transcatheter aortic valve implantation procedures.
- No significant benefit was observed with percutaneous coronary intervention revascularization in terms of 1-year mortality.
- The timing, a priori versus concomitant percutaneous coronary intervention revascularization strategies, showed comparable results.

What Are the Clinical Implications?

- Routine revascularization before or during transcatheter aortic valve implantation confers no clinical advantage with respect to several patient-important clinical outcomes.
- In the absence of definitive evidence, careful evaluation of patients by a dedicated heart team is of paramount importance to identify patients for whom the benefits of elective revascularization are balanced against the potential risks.
- Randomized controlled trials are needed to determine the role of routine revascularization in patients with significant coronary artery disease undergoing transcatheter aortic valve implantation.

Associated with worse postoperative outcomes, although with no negative impact on operative and 1-year mortality. Nevertheless, the role of revascularization in long-term morbidity and mortality in octogenarians is still not clear.

The prevalence of CAD in the population undergoing transcatheter aortic valve implantation (TAVI) is higher than that in those undergoing surgical aortic valve replacement, and depending on the definition, the presence of significant CAD ranges from 50% to 75%. Notably, randomized clinical trials that led to the approval of TAVI devices in United States required revascularization of significant CAD affecting main epicardial vessels within 30 days of TAVI. In this context, it has been recommended to perform percutaneous coronary intervention (PCI) or a hybrid procedure to revascularize patients with significant CAD.

Favorable outcomes associated with prior-TAVI PCI have been reported in single-center studies with relatively small sample sizes, although these were often underpowered for the end points studied and were subject to significant selection biases. In addition, data on whether revascularization should be performed before or in the same setting are still scant. The aim of this report was to perform a systematic review and meta-analysis to assess the evidence basis and clinical outcomes associated with TAVI procedures performed with and without revascularization of coexistent CAD with PCI.

Methods

Search Strategy

We conducted a search of Medline, Embase, Google Scholar, Science Direct, Web of Science, and conference abstracts from conception to September 2016 using OvidSP. One study published after the systematic search was updated from its previous publication in a conference abstract format and then included in the qualitative synthesis. The following terms were used: (transcatheter aortic valve implantation OR transfemoral aortic valve implantation OR transapical aortic valve implantation OR trans-subclavian aortic valve implantation OR TAVI OR transcatheter aortic valve replacement OR TAVR) AND (percutaneous coronary intervention OR PCI OR coronary angioplasty). Institutional review board approval and patient consent were not required because of the nature of this study as a systematic review and meta-analysis.

Study Selection

The abstract and titles yielded by the search were screened by 2 independent investigators (R.A.K. and C.S.K.) against the inclusion criteria. Additional studies were retrieved by checking the bibliography of included studies and relevant reviews. The full reports of potentially relevant studies were retrieved, and data were independently extracted on study design, participant characteristics, treatment groups, outcome events, follow-up, and results. Any discrepancies between reviewers were resolved by discussion after consulting a third investigator (R.B.).

Eligibility Criteria

We included only studies published in English that evaluated patients with underlying CAD who underwent PCI as a revascularization strategy prior to or concomitantly with TAVI versus no revascularization. In terms of outcomes, studies included must have evaluated ≥1 of the following...
events: 30-day and 1-year mortality, myocardial infarction (MI), vascular complications, bleeding, neurological events (stroke or transient ischemic attack), or acute kidney injury (AKI). End points were reported, when available, in accordance to Valve Academic Research Consortium 2 definitions. The reporting of outcomes had to include either crude events in each group or any risk or odds estimate (risk ratio or odds ratio [OR]) with 95% confidence intervals (CIs). There was no restriction based on the design of the study or the duration of follow-up. We excluded isolated case reports or case series (≤3 patients), reviews, and editorial comments on the subject. When duplicate reports of the same study were identified, only the report with the most complete data set and detailed methodology description was included. A flow diagram is provided following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses; Figure 1).

Quality and Risk of Bias Assessment

To assess the quality of included cohort studies, we used the Newcastle-Ottawa Scale. The outcomes of interest and follow-up were also extracted on a preformatted table. Disagreements were resolved by consensus after consultation with an investigator (R.B.). Risk of bias was assessed by considering the ascertainment of treatment groups, the ascertainment of outcomes, loss to follow-up, and potential confounders in the data analysis.

Data Analysis

We used RevMan (Review Manager version 5.1.7, Nordic Cochrane Centre, Denmark) to perform random-effects meta-analysis using the Mantel-Haenszel method to determine pooled ORs for dichotomous data with regard to post-TAVI outcomes with and without PCI revascularization. To ensure a meta-analysis with clinically transferable results, we included only studies in which the methodology or data set permitted adjudication of CAD prevalence in the TAVI-alone group. The Cochran Q statistic ($I^2$) was used to assess the consistency among studies, with $I^2<25\%$ considered low, $I^2$ values of 25% to 50% considered moderate, and $I^2>75\%$ considered high statistical heterogeneity. If there were insufficient data or studies for meta-analysis, we pooled the studies using weighted average or performed narrative synthesis of studies that were too heterogeneous to pool. Sensitivity analyses were performed to assess the potential influence of any estimates on treatment effect or association that were derived from the mean by excluding a study considered as an outlier. In addition, sensitivity analyses further assessed for potential differences between random- and fixed-effects models, excluding studies in which one of the treatment arms had no events. Subgroup analyses were performed to determine whether treatment effect was influenced by studies reporting a population with 100% versus >50% (but <100%) of the patients presenting with CAD. Meta-regression was performed to further investigate the potential source of clinical heterogeneity and to determine the influence of CAD on outcomes. The metareg function (STATA 14.0) was used to undertake metaregression with log-risk estimates and the standard error determined from 95% CIs for the log-risk estimates. Prevalence of CAD was calculated by averaging the percentage of patients with CAD in TAVI-PCI and TAVI-alone groups. Two-sided $P$ values of <0.05 were considered statistically significant.

Results

Study Population

A total of 24 observational studies including 7128 participants met the inclusion criteria for the systematic review; among these, 9 studies met criteria for the meta-analysis, evaluating 3858 participants (Figure 1) of which 983

*References 9, 10, 12, 25, 31, 32, 35, 37, 40.
underwent TAVI with PCI revascularization strategy. The mean age was 85.3 years and 48.4% were female in 14 studies that reported both age and gender. Anatomically significant CAD was inconsistently defined and included at least ≥50% diameter stenosis in 7 studies, >70% stenosis in 5 studies, and >90% stenosis in 1 study. A total of 4 studies defined >50% stenosis when located in the left main. None of the studies reported on the use of functional assessment for CAD significance. Further details on study design and participants baseline characteristics are presented in Tables 1 and 2.

Quality Assessment

Ascertainment of outcomes varied from medical record reviews to prospective evaluation with adjudicated clinical end points. All studies contained no major loss to follow-up, and the overall quality level was average. Follow-up of patients varied from in-hospital outcomes, clinical visits, and telephone calls up to 4 years from the date of implant. Although follow-up among studies was inconsistent, the most common time points were at 30 days and 1 year. The Newcastle-Ottawa quality assessment is presented in Table 3.

In-Hospital, 30-Day, and Long-Term Outcome With PCI Versus TAVI Alone

Device type, access site, procedure-related outcomes, and follow-up assessment for all included studies reporting crude rate of events are summarized in Table 4. Crude outcomes for strategies with versus without revascularization (PCI) are shown in Table 5. Crude all-cause 30-day mortality was reported in 18 studies and occurred in 6.97% (368/5281) of patients; crude cardiovascular 30-day mortality was reported in 5 studies and occurred in 5.0% (52/1046) of patients. At 30 days, the crude incidence of MI was reported in 9 studies and occurred in 0.8% (26/3109) of patients, major or life-threatening bleeding was reported in 12 studies and occurred in 14.5% (590/4074) of patients, and AKI was reported in 13 studies and occurred in 6.04% (259/4288) of patients.

Meta-analyses evaluating outcomes showed that patients who underwent revascularization were more likely to experience major vascular complications (OR: 1.86; 95% CI, 1.33–2.60; P=0.0003; heterogeneity: P=0.83, I²=0%) and higher 30-day mortality (OR: 1.42; 95% CI, 1.08–1.87; P=0.01; heterogeneity: P=0.63, I²=0%). There were no significant differences in effect estimates for 30-day cardiovascular mortality (OR: 1.03; 95% CI, 0.35–2.99), MI (OR: 0.86; 95% CI, 0.14–5.28), major or life threatening bleeding (OR: 0.82; 95% CI, 0.54–1.26), AKI and/or need for hemodialysis (OR: 0.89; 95% CI, 0.42–1.88), stroke or transient ischemic attack (OR: 1.07; 95% CI, 0.38–2.97), and the combined safety end point (OR: 0.81; 95% CI, 0.48–1.37; Figure 2).

A total of 9 studies reported 1-year mortality rates and 2 studies reported 2-year mortality rates. The crude incidence of death was 21.3% (545/2554) of patients at 1 year and 57.5% (258/449) at 2 years. Meta-analyses evaluating 1-year mortality for pre-TAVI PCI versus TAVI without revascularization showed no significant differences in point estimate (OR: 1.05; 95% CI, 0.71–1.56; P=0.81; heterogeneity: P=0.64, I²=0%; Figure 2).

Notably, although most of the included studies were small and reported neutral results, Singh et al presented a large sample size and reported adverse outcomes with PCI. In addition, the 95% CIs of all the studies except that of Singh et al overlap 1 (Figure 2), and the 95% CIs of the overall effect estimate do not overlap 1. Consequently, sensitivity analysis excluding this study showed a decrease in the effect estimates for 30-day mortality (OR: 1.15; 95% CI, 0.69–1.92; P=0.59; heterogeneity: P=0.62, I²=0%) and major vascular complications (OR: 1.38; 95% CI, 0.61–3.10; P=0.44; heterogeneity: P=0.90, I²=0%), although widening the CIs in the latter. The remaining sensitivity-analyzed outcomes remained unchanged (Figure 3).

Preprocedural Versus Same-Setting Revascularization

Revascularization PCI was performed either concomitantly with TAVI or a priori in 12 studies. Eight studies exclusively revascularized patients prior to TAVI, and 1 study did so in the same setting, and 1 study reported both strategies. Five studies reported outcomes based on PCI timing, and those who underwent prior PCI varied from same setting to 6 months prior to TAVI.

Meta-analyses evaluating a priori PCI versus concomitant revascularization strategies showed comparable effect estimates for 30-day mortality (OR: 1.28; 95% CI, 0.41–4.00), major or life threatening bleeding (OR: 0.42; 95% CI, 0.14–1.26), or major vascular complications (OR: 0.30; 95% CI, 0.04–1.98; Figure 4).

1References 9–12, 23, 26, 28, 31–33, 35, 36, 39, 40.
2References 9–12, 23, 25, 26, 28, 31–37, 39–41.
3References 10, 12, 22, 23, 28, 31–36, 39, 40.
4References 10, 11, 22, 23, 25, 27, 29, 33, 34, 38–40.
### Table 1. Study Design and Participant Characteristics

| Study                  | Design; Country; Year          | No. of Participants; PCI+TAVI; TAVI Alone | Participant Inclusion Criteria and CAD Significance Definition                                                                 |
|------------------------|-------------------------------|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Masson et al 2010      | Retrospective cohort study; Canada; 2005–2007 | 104; 15; 89                             | Patients for TAVI with $\geq 50\%$ diameter stenosis in at least 1 coronary artery and DMJS score                              |
| Conradi et al 2011     | Retrospective cohort study; Germany; 2008–2010 | 28; 28; 0                               | Patients for TAVI who underwent PCI                                                                                         |
| Gautier et al 2011     | Retrospective cohort study; France; 2006–2009 | 83; 11; 72                              | Patients for TAVI with $\geq 70\%$ epicardial coronary artery stenosis or $\geq 50\%$ stenosis of left main artery         |
| Nowakowski et al 2011  | Cohort study; Australia; Unclear | 70; 15; 55                              | Patients for TAVI with no information for determination of CAD significance                                                  |
| Wenaweser et al 2011   | Retrospective cohort study; Switzerland; 2007–2010 | 256; 59; 197                           | TAVI patient with $\geq 50\%$ diameter stenosis in at least 1 coronary artery                                                |
| Abdel-Wahab et al 2012 | Retrospective cohort study; Germany; 2007–2011 | 125; 55; 70                             | TAVI patients with $\geq 50\%$ stenosis on angiography or previous cardiac event                                            |
| Bensaid et al 2012     | Cohort study; France; Unclear | 61; 23; 38                              | TAVI patients with $\geq 70\%$ proximal vessel stenosis                                                                    |
| Aktug et al 2013       | Cohort study; Germany; 2008–2012 | 338; 66; 272                            | Patients for TAVI with CAD defined as clinically significant                                                                |
| Arnold et al 2013      | Retrospective cohort study; Germany; Unclear | 300; 73; 227                            | Patients for TAVI with CAD defined as clinically significant                                                                |
| Codner et al 2013      | Retrospective cohort study; Israel; 2008–2012 | 153; 36; 117                            | Patients for TAVI with CAD defined as clinically significant                                                                |
| Czerwinska-Jelonkiewicz et al 2013 | Retrospective cohort study; Poland; 2009–2011 | 83; 18; 65                              | Not reported                                                                                                                  |
| Gasparetto et al 2013  | Retrospective cohort study; Italy; Unclear | 152; 39; 113                            | Patients for TAVI with $\geq 50\%$ diameter stenosis of at least 1 epicardial coronary artery                               |
| Van Mieghem et al 2013 | Retrospective cohort study; Netherlands; 2005–2012 | 138; 39; 99                             | Patients for TAVI with $\geq 50\%$ diameter stenosis in any coronary artery                                                 |
| Abramowitz et al 2014  | Retrospective cohort study; Israel; 2009–2012 | 144; 61; 83                             | TAVI patients with $\geq 70\%$ stenosis in major epicardial coronary artery                                                |
| Griese et al 2014      | Retrospective cohort study; Germany; 2009–2012 | 411; 65; 346                            | TAVI patients with CAD significance defined as per the institution’s current local practice                                   |
| Tatar et al 2014       | Retrospective cohort study; France; 2008–2013 | 141; 38; 103                            | Patients for TAVI but no information of determination of CAD significance                                                   |
| Khawaja et al 2015     | Retrospective cohort study; United Kingdom; 2008–2012 | 93; 25; 68                              | Patients for TAVI with epicardial coronary artery stenosis $\geq 70\%$ or left main stem stenosis of $\geq 50\%$          |
| Mancio et al 2015      | Retrospective cohort study; Portugal; 2007–2012 | 46; 13; 33                              | Patients for TAVI with $\geq 50\%$ stenosis in coronary artery                                                             |
| Penkalla et al 2015    | Retrospective cohort study; Germany; 2008–2013 | 308; 76; 232                            | $\geq 50\%$ stenosis in left main or $\geq 90\%$ stenosis in LAD, LCx, and RCA                                              |
| van Rosendael et al 2015 | Retrospective cohort study; Netherlands, Unclear | 96; 96; 0                                | TAVI patients with $\geq 70\%$ stenosis of a coronary artery of $\geq 1.5$ mm                                                  |
| Snow et al 2015        | Retrospective cohort study; United Kingdom; 2007–2011 | 1339; 172; 1167                       | TAVI patients with $\geq 50\%$ stenosis main, LAD, LCx, and RCA                                                            |
| Chakravarty et al 2016 | Retrospective cohort and matched study; International; 2007–2014 | 256 (cohort); 128; 128                 | Patients with left main PCI from a TAVI-left main registry and matched controls                                             |
| Singh et al 2016      | Retrospective cohort study with propensity matching; United States of America; 2011–2013 | 2349; 588; 1761                        | TAVI patients with CAD according to ICD-9 coding                                                                            |
| Paradis et al 2017     | Retrospective cohort study; North America; 2007–2012 | 377; 54; 323                            | Patients for TAVI with CAD defined as significant if $\geq 50\%$ of vessel diameter                                          |

CAD indicates coronary artery disease; DMJS, Duke Myocardial Jeopardy score; ICD-9, International Classification of Diseases, Ninth Revision; LAD, left anterior descending; LCx, left coronary circumflex; PCI, percutaneous coronary intervention; RCA, right coronary artery; TAVI, transcatheter aortic valve implantation.
### Table 2. Baseline Characteristics for Patients Who Underwent TAVI With and Without PCI

| Study                  | Strategy       | Mean Age (Y) | Male | Logistic EuroSCORE | STS Score | CAD | Multivessel Disease | LVEF | CKD | COPD | PVD |
|------------------------|----------------|--------------|------|--------------------|-----------|-----|---------------------|------|-----|------|-----|
| Masson et al 2010      | TAVI-PCI       | 85.7         | 10 (66.6) | 24.5               | 9.5       | 15 (100) | N/A                | 45.0 | 0 (0) | N/A | 3 (20.0) |
|                        | TAVI alone     | 84.4         | 60 (57.8) | 31.05              | 9.7       | 104 (100) | 58.4             | 93 (89.4) | 42 (40.3) |
| Conradi et al 2011     | TAVI-PCI       | 80.1         | 13 (46.4) | 26.8               | 9.3       | 28 (100) | 19 (67.9) | 45.6 | 8 (28.6) | 7 (25.0) | 11 (39.3) |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Gautier et al 2011     | TAVI-PCI       | 74±15        | 9 (81.8) | 25±11              | N/A       | N/A      | N/A               | 11 (100) | 7 (63.6) | 48±13 | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Nowakowski et al 2011  | TAVI-PCI       | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Wenaweser et al 2011   | TAVI-PCI       | 83.6±4.8     | 29 (49.2) | 26.8±16.3          | 7.6±6.2   | 59 (100) | N/A               | 51±12 | N/A | N/A | 16 (27.1) |
|                        | TAVI alone     | 81.7±6.5     | 83 (42.1) | 24.2±14.4          | 6.1±4.5   | 108 (54.8) | N/A               | 51±15 | N/A | N/A | 48 (24.4) |
| Abdel-Wahab et al 2012 | TAVI-PCI       | 81±7.1       | 26 (47.0) | 25.08±12.6         | N/A       | 55 (100) | 18 (32.7) | 46.9±13.9 | N/A | N/A | 11 (20.0) |
|                        | TAVI alone     | 81±6.2       | 34 (48.5) | 23.62±15.1         | N/A       | 36 (51.4) | 27 (38.6) | 48.5±15.3 | N/A | N/A | 10 (14.2) |
| Bensaid et al 2012     | TAVI-PCI       | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Aktug et al 2013       | TAVI-PCI       | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | 66 (100) | N/A | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | 155 (57) | N/A | N/A | N/A |
| Arnold et al 2013      | TAVI-PCI       | 82±6         | 39 (54)  | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
|                        | TAVI alone     | 81±6         | 78 (44)  | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Codner et al 2013      | TAVI-PCI       | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Czerniakowska-Jelonkiewicz et al 2013 | TAVI-PCI     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | N/A | N/A | N/A | N/A |
| Gasparetto et al 2013   | TAVI-PCI       | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | 39 (100) | N/A | N/A | N/A |
|                        | TAVI alone     | 80.3±6.3     | 57 (50.4) | 23.2±14.1          | N/A       | 113 (100) | 52.8±12.9 | 65 (57.5) | 25 (22.1) |
| Van Mieghem et al 2013 | TAVI-PCI       | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | 39 (100) | N/A | N/A | N/A |
|                        | TAVI alone     | N/A          | N/A      | N/A                | N/A       | N/A      | N/A               | 99 (100) | N/A | N/A | N/A |
| Abramowitz et al 2014  | TAVI-PCI       | 83.6±5.5     | 33 (50.8) | 31.3±13.8          | N/A       | 61 (100) | 35 (57.4) | 54.6±9 | N/A | 7 (11.5) | 10 (16.4) |
|                        | TAVI alone     | 83.1±5.1     | 40 (48.2) | 29.2±13.8          | N/A       | 83 (100) | 47 (56.7) | 55.2±7.5 | N/A | 21 (25.3) | 14 (16.9) |
| Griese et al 2014      | TAVI-PCI       | 82±6         | 24 (36.9) | 21.7±13.9          | N/A       | N/A      | N/A               | 52±15 | 36 (55.3) | N/A | N/A |
|                        | TAVI alone     | 82±5         | 129 (37.3) | 20.3±14.6          | N/A       | N/A      | N/A               | 54±14 | 177 (51.2) | N/A | N/A |
| Study                  | Strategy   | Mean Age (Y) | Male | Logistic EuroSCORE | STS Score | CAD | MultivesSEL Disease | LVEF | CKD | COPD | PVD |
|-----------------------|------------|--------------|------|--------------------|-----------|-----|---------------------|------|-----|------|-----|
| Tatar et al 2014      | TAVI+PCI   | 85.5±5       | 18 (47.4) | 31.3±16.6          | 7.8±5.8   | 38 (100) | 19 (50.0)          | N/A  | 11 (29.0) | 8 (21.1) | 8 (21.1) |
|                       | TAVI alone | 84±6         | 54 (52.0) | 31.7±16.8          | 7.5±4.7   | 54 (52.4) | 10 (9.7)           | 41 (39.8) | 35 (34.0) | 41 (39.8) |
| Khawaja et al 2015    | TAVI+PCI   | N/A          | N/A  | N/A                | N/A       | N/A | N/A                 | N/A  | N/A | N/A  | N/A |
|                       | TAVI alone | N/A          | N/A  | N/A                | N/A       | N/A | N/A                 | N/A  | N/A | N/A  | N/A |
| Mancio et al 2015     | TAVI+PCI   | N/A          | N/A  | N/A                | N/A       | N/A | N/A                 | N/A  | N/A | N/A  | N/A |
|                       | TAVI alone | N/A          | N/A  | N/A                | N/A       | N/A | N/A                 | N/A  | N/A | N/A  | N/A |
| Penkalla et al 2015   | TAVI+PCI   | 83 (78–86)   | 21 (27.6) | 32.1 (19–52)       | 11.9 (7–19) | 76 (100) | N/A                 | 55 (40–60) | N/A | N/A | 50 (65.8) |
|                       | TAVI alone | 81 (76–85)   | 88 (37.9) | 28.5 (18–45)       | 10.1 (6–19) | 232 (100) | N/A                 | 50 (41–60) | N/A | N/A | 160 (69.0) |
| van Rosendaal et al 2015 | TAVI+PCI   | 81±5.4       | 55 (57.3) | 23.2±12.9          | N/A       | 96 (100) | N/A                 | 54±13 | N/A | N/A | N/A |
|                       | TAVI alone | N/A          | N/A  | N/A                | N/A       | N/A | N/A                 | N/A  | N/A | N/A | N/A |
| Snow 2015             | TAVI+PCI   | N/A          | N/A  | N/A                | N/A       | 172 (100) | N/A                 | N/A  | N/A | N/A | N/A |
|                       | TAVI alone | N/A          | N/A  | N/A                | 1167 (100) | N/A | N/A                 | N/A  | N/A | N/A | N/A |
| Chakravarty 2016      | TAVI+PCI   | 81.7±6.8     | 81 (63.3) | N/A                | 7.8±4.9   | 128 (100) | N/A                 | 53.5±12.4 | N/A | N/A | 44 (34.4) |
|                       | TAVI alone | 81.0±7.9     | 88 (68.7) | 8.0±4.5            | 128 (100) | N/A | N/A                 | 55.5±13.6 | N/A | N/A | 50 (41.4) |
| Singh et al 2016      | TAVI+PCI   | 83.0±0.59    | 279 (47.4) | N/A                | 493 (83.9) | N/A | N/A                 | 164 (27.9) | 189 (32.2) |
|                       | TAVI alone | 82.9±0.39    | 812 (46.1) | N/A                | 1125 (63.9) | N/A | N/A                 | 560 (31.8) | 526 (29.9) |
| Paradis et al 2017    | TAVI+PCI   | N/A          | 39 (39.8) | N/A                | SYNTAX    | N/A | N/A                 | N/A  | N/A | N/A | N/A |
|                       | TAVI alone | 160 (56.3)   | N/A  | N/A                | 22.0       | 18.5 | N/A                 | N/A  | N/A | N/A | N/A |

Data presented as number/sample size (percentage), mean±SD or median (interquartile range). CAD indicates coronary artery disease; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; Log-EuroSCORE, logistic European system for cardiac operative risk evaluation; LVEF, left ventricle ejection fraction; N/A, not available; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STS score, Society of Thoracic Surgeons Score for Prediction of Mortality score; SYNTAX, Synergy Between PCI With Taxus and Cardiac Surgery; TAVI, transcatheter aortic valve implantation.
Table 3. Newcastle-Ottawa Quality Assessment Scale

| Study                  | Sample Size >50 in Each Arm | Representativeness of Exposed Cohort for TAVI Population | Selection of Non-Exposed Cohort | Method of Exposure Ascertainment | Outcome of Interest Present at Start? | Adjustment for Important Confounders | OutcomeAscertainment (Source, Criteria) | Adequate Length of Follow-up <10% | Loss to Follow-up | Overall Quality |
|------------------------|------------------------------|--------------------------------------------------------|--------------------------------|---------------------------------|--------------------------------------|-------------------------------------|--------------------------------------|-------------------------------|-----------------|----------------|----------------|
| Masson et al 2010⁹     | No, 15 and 89                | Yes                                                    | All in our analysis had CAD of varying severity | Preoperative coronary angiography and Duke Myocardial Jeopardy score | No                                   | Both groups in our analysis had 100% CAD but no other adjustments | Clinical appointment follow-up but adjudication not according to standardized end points | Yes                           | Yes, unclear    | Average        |
| Conradi et al 2011⁵⁵  | No, 28                       | Yes                                                    | All had CAD                    | Preoperative coronary angiography | No                                   | Both groups had 100% CAD but no other adjustments | Telephone interviews but no adjudication according to guidelines | Yes                           | Yes, none        | High           |
| Gautier et al 2011¹¹   | No, 11 and 72                | Yes                                                    | All had CAD                    | Preoperative coronary angiography | No                                   | No adjustment                      | Unclear, but adjudicated according to guidelines for reporting mortality and morbidity in TAVI | Yes                           | Yes, none        | Average        |
| Nowakowski et al 2011²²| No, 15 and 55                | Yes                                                    | No information on CAD prevalence | Unclear                          | Unclear                              | No reporting of CAD percentage in each arm or other adjustments | Unclear                          | Unclear          | Unclear        | Low            |
| Wenaweser et al 2011¹⁰| Yes, 59 and 197               | Yes                                                    | Dissimilar CAD distribution between exposed and non-exposed cohorts | Preprocedural left heart catheterization | No                                   | No adjustments, imbalance in CAD between arms | Data from municipal civil registries and hospital records; data recorded in accordance with VARC guidelines but version is unclear | Yes                           | Yes, none        | Average        |
| Abdel-Wahab et al 2012¹²| Yes, 55 and 70               | Yes                                                    | Nonexposed cohort had different rate of CAD | Preoperative coronary angiography | No                                   | No, not controlling for CAD           | No information on source employed; outcomes adjudicated in accordance with VARC-1 guidelines | Yes                           | Yes, 0.8% loss to follow-up | Average        |
| Study                        | Sample Size >50 in Each Arm | Representativeness of Exposed Cohort for TAVI Population | Selection of Non-Exposed Cohort | Method of Exposure Ascertainment | Outcome of Interest Present at Start? | Adjustment for Important Confounders | Outcome Ascertainment (Source, Criteria) | Adequate Length of Follow-up | Loss to Follow-up <10% | Overall Quality |
|-----------------------------|-----------------------------|-----------------------------------------------------------|--------------------------------|----------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|-----------------------------|--------------------------|------------------|
| Bensaid et al 2012<sup>24</sup> | No, 23 and 38               | Yes                                                       | No information on CAD prevalence | Preoperative coronary angiography | Unclear                              | CAD percentage same in both groups but no other adjustments | Unclear source and adjudication guidelines | Yes                         | Unclear                  | Low              |
| Aktug et al 2013<sup>25</sup> | Yes, 66 and 272             | Yes                                                       | Dissimilar CAD distribution between exposed and nonexposed cohorts | Unclear                          | No                                   | No, not controlling for CAD or other factors       | Unclear source and adjudication guidelines | Yes                         | Unclear                  | Low              |
| Arnold et al 2013<sup>26</sup> | Yes, 73 and 227             | Yes                                                       | No information on CAD prevalence | Unclear                          | Unclear                              | No, not controlling for CAD or other factors       | Unclear source and adjudication guidelines | Yes                         | Unclear                  | Low              |
| Codner et al 2013<sup>27</sup> | No, 36 and 117              | Yes                                                       | No separate information on CAD prevalence | Preoperative coronary angiography | No                                   | No adjustments                                 | Participants prospectively examined; data recorded in accordance with VARC-1 criteria | Yes                         | Yes, none              | Average          |
| Czerninska-Jelonkiewicz et al 2013<sup>28</sup> | No, 18 and 65               | Yes                                                       | No information on CAD prevalence | Unclear                          | No                                   | No adjustments                                 | Telephone interviews; data recorded in accordance with VARC-1 criteria | Yes                         | Yes, 2.4% loss to follow-up | Low              |
| Gasparetto et al 2013<sup>29</sup> | No, 39 and 113              | Yes                                                       | All had CAD                       | Preoperative coronary angiography or history | No                                   | No adjustments                                 | Unclear; data recorded in accordance with VARC-1 criteria | Yes                         | Yes, none           | Average          |
| Van Mieghem et al 2013<sup>29</sup> | No, 39 and 99               | Yes                                                       | Unclear                           | Preoperative coronary angiography | No                                   | No adjustments                                 | Clinical follow-up; VARC-1 criteria | Yes                         | Yes, none           | Average          |
| Abramowitz et al 2014<sup>31</sup> | Yes, 61 and 83              | Yes                                                       | Nonexposed cohort similar to exposed in terms of CAD | Preprocedural coronary angiography | No                                   | Yes, controlling for CAD                   | Outcomes prospectively recorded in clinical assessments employing VARC-1 guidelines | Yes                         | Yes, none          | High             |
Table 3. Continued

| Study               | Sample Size >50 in Each Arm | Selection Bias          | Representativeness of Exposed Cohort for TAVI Population | Selection of Non-Exposed Cohort | Method of Exposure Ascertainment | Outcome of Interest Present at Start? | Adjust for Important Confounders | Outcome Ascertainment (Source, Criteria) | Adequate Length of Follow-up < 10% | Loss to Follow-up | Overall Quality |
|---------------------|-----------------------------|-------------------------|----------------------------------------------------------|--------------------------------|-----------------------------------|--------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|----------------|-----------------|
| Griese et al 2014   | Yes 65 and 346              | Yes                     | No information on CAD prevalence                        | Preoperative cardiac catheterization | No                                | No adjustment and CAD percentage unreported | Yes, phone calls; data recorded in accordance with VARC-2 criteria | Yes, 100% follow-up                   | Average                   |
| Tatar et al 2014    | Yes, 38 and 103             | Yes                     | Nonexposed cohort had different rate of CAD             | Unclear                          | No                                | No adjustments, imbalance in CAD between arms | Unclear                             | Yes, none                           | Low                      |
| Khawaja et al 2015  | No, 25 and 68               | Yes                     | All patients in analyzed subgroup had CAD               | Pre-TAVI coronary angiogram and SYNTAX score calculation | No                                | In the subgroup analysis, all patients had CAD but no other adjustments | Database with outcomes reported according to VARC-2 criteria | Yes, none                           | High                     |
| Mancio et al 2015   | No, 13 and 33               | Yes                     | All had CAD                                             | Preprocedural coronary angiography | No                                | 100% CAD in both groups, no other adjustments | Unclear                             | Yes, none                           | High                     |
| Penkalla et al 2015 | Yes, 76 and 232             | Yes                     | Information on CAD present and stratified according to significance | Pre-TAVI coronary angiogram and SYNTAX score calculation | No                                | Adjusted for comparison between groups II and III, as they all had CAD; no other adjustments | Mortality ascertained from German Register of Residents and clinical outcomes from prospective e-database; ascertainment according to VARC-2 consensus guidelines | Yes                    | Unclear                    |
| van Rosendaal et al 2015 | No, 96                   | Yes                     | All had CAD                                             | Preoperative coronary angiograms with SYNTAX score calculation | No                                | No adjustments                                       | Electronic record keeping, using VARC-2 criteria | Yes                    | Yes, none                      | Average                   |
| Snow et al 2015     | Yes, 172 and 2416           | Yes                     | Unequal CAD distribution between exposed and nonexposed | Pre-TAVI coronary angiogram       | No                                | No adjustments                                       | Prospectively entered data from electronic BCIS and SCTS database; data linked to the Office of National Statistics and | Yes                    | Unclear                    | Average                   |
Table 3. Continued

| Study                      | Sample Size >50 in Each Arm | Selection Bias | Outcome of Interest Present at Start? | Adjustment for Important Confounders | Outcome Ascertainment (Source, Criteria) | Adequate Length of Follow-up <10% | Loss to Follow-up | Overall Quality |
|---------------------------|-----------------------------|----------------|----------------------------------------|---------------------------------------|------------------------------------------|-----------------------------------|------------------|-----------------|
| Chakravarty et al 2016   | Yes, 128 and 128            | Yes            | No                                     | No                                    | Data from registry, recorded in accordance with VARC-2 guidelines | Yes                               | Yes, none        | High            |
|                           |                             |                | No information on CAD prevalence but matched for unprotected left main stem |                                      |                                          |                                   |                  |                 |
| Singh et al 2016          | Yes, 588 and 1761           | Yes            | No                                     | Clear                                 | Outcomes ascertained via the Nationwide Inpatient sample; ICD-9 codes used | Yes                               | Yes, none        | Average         |
|                           |                             |                | No information on how significance was determined |                                      |                                          |                                   |                  |                 |
| Paradis et al 2017        | Yes, 98 and 285             | Yes            | No                                     | Multivariate analysis for mortality but not for other outcomes; no data on variables included in the model | Adjudicated outcomes according to VARC-1 definition by clinical event committee | Yes                               | Unclear          | Average         |

BCIS indicates British Cardiovascular Intervention Society; CAD, coronary artery disease; ICD-9, International Classification of Diseases, Ninth Revision; SCTS, Society of Cardiothoracic Surgeons; TAVI, transcatheter aortic valve implantation; VARC, Valve Academic Research Consortium.
Table 4. Procedure-Related Complications and Follow-up Clinical Outcome

| Study                | Type of Valve Approach               | Timing of PCI                        | Outcomes                  | TAVI-PCI | TAVI Alone |
|---------------------|-------------------------------------|--------------------------------------|---------------------------|----------|-----------|
| Mason et al 2010    | Edwards SAPIEN (100%)               | Transfemoral: 82/119 (69%)           | 30-ay mortality           | 0/15 (0) | 12/89 (14)|
|                     | Transapical: 17/28 (61%)            | Concomitant                         | 1-y mortality            | 3/15 (20)| 26/89 (29)|
|                     |                                     | A priori                             |                           |          |           |
|                     |                                     | Median: 26 d                         |                           |          |           |
|                     |                                     | Range: 3–100 d                       |                           |          |           |
| Conradi et al 2011  | Medtronic CoreValve                 | Concomitant and a priori up to 4 w   | Procedural and 30-d mortality | 2/7 (29) | 0/21 (0)  | N/A       |
|                     | Edwards SAPIEN (100%)               | before TAVI                          | AKI                       | 2/7 (29) | 0/21 (0)  |           |
|                     | Transfemoral: 11/28 (39%)           |                                     | Nonsevere bleeding        | 0/7 (0)  | 2/21 (10) |           |
| Gautier et al 2011  | Medtronic CoreValve                 | Concomitant and a priori, mean delay | 30-d mortality           | 8/83 (9.6)|          |           |
|                     | Edwards SAPIEN                      | 6±6 w                                | Stroke                    | 2/83 (2.4)|          |           |
|                     | Transfemoral                        |                                     | MI                        | 8/83 (9.6)|          |           |
|                     | Trans-subclavian                    |                                     | Severe bleeding           | 5/83 (6.0)|          |           |
|                     |                                     |                                     | Vascular complications    | 9/83 (11)|          |           |
| Nowakowski et al    | N/A                                 | Concomitant and a priori, at least 6 | Stroke                    | 0/6 (0)  | 1/9 (11.1)|           |
| 2011                |                                     | w prior to TAVI in all but 6 patients| AKI                       | 0/6 (0)  | 2/9 (22)  | N/A       |
|                     |                                     |                                     | Vascular complications    | 1/6 (17) | 0/9 (0)  |           |
| Wenaweser et al 2011| Medtronic CoreValve                 | Concomitant and a priori             | Concomitant               | 4/36 (11)| 2/23 (8.7)| 11/197 (5.6)|
|                     | Edwards SAPIEN                      |                                     | A priori                  | 3/59 (5.1)| 9/197 (4.6)|           |
|                     | Transfemoral                        | 30-d mortality                       | 30-d cardiovascular mortality | 2/36 (5.6)| 0/23 (0)  | 8/197 (4.1)|
|                     | Trans-subclavian                    | 30-d stroke                          | 30-d MI                   | 0/36 (0) | 0/23 (0)  | 1/197 (0.5)|
|                     | Transapical                         | 30-d MI                              | Life-threatening bleeding | 2/36 (5.6)| 3/23 (13) | 24/197 (12)|
|                     |                                     | Major bleeding                        | Major access site-related complication | 21/59 (36) | 57/197 (29) |           |
|                     |                                     | 2/36 (6.6)                           | Minor access site-related complication | 0/36 (2.8) | 12/197 (6.1) |           |
|                     |                                     | 3/23 (13)                            | Combined safety end point | 5/59 (8.5) | 18/197 (9.1) |           |
|                     |                                     | 2/23 (8.7)                           | AKI (I, II, and III)      | 8/36 (2.2) | 6/23 (26) | 61/197 (31)|
|                     |                                     | 3/23 (13)                            | Permanent pacemaker implantation | 14/59 (24)| 46/197 (23) |           |
|                     |                                     | 30-d mortality                       | 30-d mortality            | 1/55 (1.8) | 4/70 (5.7) |           |
| Study                  | Type of Valve Approach                      | Timing of PCI               | Outcomes                                   | TAVI+PCI | TAVI Alone |
|-----------------------|---------------------------------------------|-----------------------------|--------------------------------------------|----------|-----------|
| Abdel-Wahab et al 2012 | Medtronic CoreValve Transfemoral: 124/125 (99.2%) Trans-subclavian: 1/125 (0.8%) | A priori Median: 10 d Range: 0–90 d | 30-d cardiovascular mortality 1/55 (1.8) 30-d stroke 1/55 (1.8) 30-d MI 0/55 (0) 30-d life threatening bleeding 4/55 (7.3) 30-d major bleeding 6/55 (11) 30-d minor bleeding 4/55 (7.3) 30-d major vascular complications 3/55 (5.5) 30-d minor vascular complications 8/55 (15) 30-d combined safety end point 6/55 (11) 30-d permanent pacemaker 16/55 (30) 30-d hemodialysis 0/55 (0) 6-Month mortality 4/48 (8.3) 6-Month coronary events 2/48 (4.2) 6-Month stroke 2/48 (4.2) 6-Month bleeding 10/48 (21) 6-Month permanent pacemaker 16/48 (33) 6-Month hemodialysis 0/48 (0) | 3/70 (4.3) 4/70 (5.7) 0/70 (0) 4/70 (5.7) 8/70 (11) 3/70 (4.3) 2/70 (2.9) 10/70 (14) 9/70 (13) 11/70 (16) 2/70 (2.9) 8/59 (14) 0/59 (0) 3/59 (5.1) 13/59 (22) 11/59 (19) 1/59 (1.7) |
| Bensaid et al 201224 | Medtronic CoreValve | A priori 1 Month prior to TAVI | Composite of heart failure, MI, and mortality 6/23 (26) | 12/38 (32) |
| Aktug et al 201325 | Medtronic CoreValve: 183/338 (54.1%) Edwards SAPIEN: 146/338 (43.2%) Symetis Acurate: 9/338 (2.7%) | Concomitant and a priori Mean: 13±9 d | 30-d mortality 8/66 (12) | 27/272 (9.9) |
| Arnodo et al 201326 | Balloon-expandable valve Transapical: 200/300 (66.7%) Transfemoral: 100/300 (33.3%) | N/A | 30-d mortality 8/73 (11) | 26/227 (12) |
| Codner et al 201327 | Medtronic CoreValve Edwards-SAPIEN Transfemoral: 112/153 (73.2%) Transapical: 27/153 (17.6%) Transaxillary: 13/153 (8.5%) Transaortic: 1/153 (0.6%) | Concomitant and a priori | 1-y mortality 5/36 (14) | 8/117 (6.8) |
Table 4. Continued

| Study                        | Type of Valve Approach                  | Timing of PCI                        | Outcomes                              | TAVI + PCI | TAVI Alone |
|------------------------------|----------------------------------------|--------------------------------------|---------------------------------------|------------|------------|
| Czerwinska-Jelonkiewicz et al 2013<sup>30</sup> | Medtronic CoreValve Edwards SAPIEN/SAPIEN-XT Transfemoral 59/83 (71%) Trans-subclavian 8/83 (9.6%) Transapical 16/83 (19.2%) | N/A                                  | Bleeding complications               | 17/18 (94) | 34/65 (52) |
| Gasparetto et al 2013<sup>28</sup> | Medtronic CoreValve Edwards SAPIEN/SAPIEN-XT Transfemoral Trans-subclavian | A priori Median: 27 (IQR 8–51) d     | 30-d mortality                        | N/A        | 5/113 (4.4) |
|                              |                                        |                                      | 30-d cardiovascular mortality         | N/A        | 6/113 (5.3) |
|                              |                                        |                                      | 30-d Stroke                           | N/A        | 3/113 (2.7) |
|                              |                                        |                                      | 30-d MI                               | N/A        | 5/113 (4.4) |
|                              |                                        |                                      | 30-d life-threatening bleeding        | N/A        | 4/113 (3.5) |
|                              |                                        |                                      | 30-d major vascular complications     | N/A        | 7/113 (6.2) |
|                              |                                        |                                      | 30-d combined safety end point        | N/A        | 12/113 (11) |
|                              |                                        |                                      | 30-d AKI (stage III)                  | N/A        | 6/113 (5.3) |
|                              |                                        |                                      | 1-y mortality                         | N/A        | 16/106 (15) |
|                              |                                        |                                      | 1-y cardiovascular mortality          | N/A        | 4/106 (3.8) |
|                              |                                        |                                      | 1-y major stroke                      | N/A        | 1/106 (0.9) |
|                              |                                        |                                      | 1-y MI                                | N/A        | 2/106 (1.9) |
|                              |                                        |                                      | 1-y major bleeding                    | N/A        | 1/106 (0.94) |
| Van Mieghem et al 2013<sup>29</sup> | Medtronic CoreValve Edwards SAPIEN Transfemoral Transaxillary, Transapical | Concomitant and a priori              | N/A                                  | N/A        | N/A        |
| Abramowitz et al 2014<sup>31</sup> | Medtronic CoreValve Edwards SAPIEN Transfemoral Trans-subclavian | A priori Mean: 56.5±29.4 d           | 30-d mortality                        | 1/61 (1.6) | 2/83 (2.4) |
|                              |                                        |                                      | 30-d stroke                           | 2/61 (3.3) | 2/83 (2.4) |
|                              |                                        |                                      | 30-d MI                               | 0/61 (0)  | 0/83 (0)   |
|                              |                                        |                                      | 30-d major bleeding                   | 2/61 (3.3) | 1/83 (1.2) |
|                              |                                        |                                      | 30-d major vascular complications     | 3/61 (4.9) | 2/83 (2.4) |
|                              |                                        |                                      | 30-d minor vascular complications     | 9/61 (1.5) | 4/83 (4.8) |
|                              |                                        |                                      | 30-d combined safety end point        | 5/61 (8.2) | 5/83 (6.0) |
|                              |                                        |                                      | 30-d permanent pacemaker              | 13/61 (21.3) | 22/83 (26.5) |
|                              |                                        |                                      | 30-d hemodialysis                     | 0/61 (0)  | 0/83 (0)   |
**Table 4. Continued**

| Study                        | Type of Valve Approach | Timing of PCI | Outcomes                        | TAVI+PCI | TAVI Alone |
|-----------------------------|------------------------|---------------|---------------------------------|----------|-----------|
| Griese et al 2014<sup>33</sup> | Medtronic CoreValve Edwards SAPIEN-XT Symetis Acurate | Concomitant and a priori, 36±38 d | 30-d mortality                  | 3/17 (18) | 7/48 (15) |
|                             |                        |               | 30-d cardiovascular mortality    | 3/17 (18) | 7/48 (15) |
|                             |                        |               | 30-d stroke                      | 0/17 (0)  | 0/48 (0)  |
|                             |                        |               | 30-d MI                          | 2/17 (1.2)| 2/48 (4.2)|
|                             |                        |               | 30-d major bleeding              | 3/17 (1.7)| 7/48 (15) |
|                             |                        |               | 30-d major vascular complications| 0/10 (0) | 1/23 (4.4)|
|                             |                        |               | 30-d permanent pacemaker         | 4/17 (2.4)| 13/48 (2.7)|
|                             |                        |               | 30-d stage III AKI               | 1/17 (5.9)| 2/48 (4.2)|
| Tatar et al 2014<sup>32</sup> | Medtronic CoreValve: 8/141 (5.7%) Edwards SAPIEN: 126/141 (89.4%) St. Jude Portico: 7/141 (4.96%) | In hospital mortality | 2/38 (5.3) | 2/103 (1.9)|
|                             |                        |               | Cardiovascular mortality         | 1/38 (2.6)| 1/103 (1.0)|
|                             |                        |               | Stroke                          | 2/38 (5.3)| 1/103 (1.9)|
|                             |                        |               | MI                              | 0/38 (0)  | 0/103 (0)  |
|                             |                        |               | Life-threatening bleeding        | 0/38 (0)  | 2/103 (1.9)|
|                             |                        |               | Major bleeding                   | 0/38 (0)  | 1/103 (1.0)|
|                             |                        |               | Minor bleeding                   | 0/38 (0)  | 0/103 (0)  |
|                             |                        |               | Major vascular complications     | 1/38 (2.6)| 3/103 (2.9)|
|                             |                        |               | Minor vascular complications     | 0/38 (0)  | 2/103 (1.9)|
|                             |                        |               | New pacemaker                   | 2/38 (5.3)| 10/103 (9.7)|
|                             |                        |               | AKI stage I, II, and III         | 13/38 (34)| 17/103 (17)|
|                             |                        |               | 1-y mortality                    | 11/38 (29)| 21/103 (20)|
|                             |                        |               | 2-y mortality                    | 13/38 (34)| 48/103 (47)|
| Khawaja et al 2015<sup>37</sup> | Edwards SAPIEN         | A priori      | 30-d mortality                  | 2/25 (8)  | 5/68 (7.4) |
|                             |                        | Median: 49.5 (IQR 25–127) d | 1-y mortality                    | 6/25 (24) | 15/68 (22) |
| Mancio et al 2015<sup>34</sup> | Medtronic CoreValve Edwards SAPIEN | Concomitant (2/13) and a priori (11/13) | 30-d mortality                  | 2/13 (15) | 4/33 (12) |
|                             |                        | Median: 56 (IQR 3–166) d | 30-d stroke                      | 1/13 (7.7)| 1/33 (3.0) |
|                             |                        |               | 30-d life-threatening bleeding   | 2/13 (15) | 10/33 (30) |
|                             |                        |               | 30-d major vascular complications| 2/13 (15) | 11/33 (33) |
|                             |                        |               | 30-d AKI                        | 4/13 (31) | 10/33 (30) |

DOI: 10.1161/JAHA.117.005960

Journal of the American Heart Association
### Table 4. Continued

| Study                      | Type of Valve Approach       | Timing of PCI                      | Outcomes                              | TAVI+PCI                  | TAVI Alone                |
|----------------------------|------------------------------|------------------------------------|---------------------------------------|---------------------------|---------------------------|
| Penkalla et al 2015         | Edwards SAPIEN (100%)        | Concomitant                        | 30-d permanent pacemaker              | 3/13 (23)                 | 13/33 (39)                |
|                            | Transapical (100%)           |                                    | 30-d mortality                        | 2/76 (2.6)                | 9/232 (3.9)               |
|                            |                              |                                    | Peri- and postprocedural MI           | 1/76 (1.3)                | 4/232 (1.7)               |
|                            |                              |                                    | AKI stage I and III                   | 16/76 (21)                | 43/232 (19)               |
|                            |                              |                                    | 1-y mortality                         | 30/76 (40)                | 94/232 (41)               |
|                            |                              |                                    | 2-y mortality                         | 46/76 (61)                | 151/232 (65)              |
|                            |                              |                                    | 3-y mortality                         | 63/76 (83)                | 188/232 (81)              |
|                            |                              |                                    | 4-y mortality                         | 73/76 (96)                | 221/232 (95)              |
| van Rosendael et al 2015    | Medtronic CoreValve          | A priori                           | A priori ≥30 d                        |                          |                          |
|                            | Edwards SAPIEN               |                                    | 30-d stroke                           | 4/48 (8.3)                | 2/48 (4.2)                | N/A                      |
|                            | Transfemoral                 |                                    | 30-d major bleeding                   | 4/48 (8.3)                | 4/48 (8.3)                |
|                            | Transapical                 |                                    | 30-d minor bleeding                   | 0/48 (0)                  | 6/48 (13)                 |
|                            |                              |                                    | 30-d major vascular injury            | 3/48 (7.3)                | 5/48 (10)                 |
|                            |                              |                                    | 30-d minor vascular injury            | 1/48 (2.1)                | 8/48 (17)                 |
|                            |                              |                                    | 30-d combined safety end point        | 9/48 (19)                 | 6/48 (13)                 |
|                            |                              |                                    | 30-d AKI                              | 8/48 (17)                 | 8/48 (17)                 |
|                            |                              |                                    | 30-d atrioventricular block           | 7/48 (7.3)                | 2/48 (4.2)                |
| Snow et al 2015            | N/A                          | Concomitant and a priori           | 1-y mortality                         | 36/172 (21)               | 246/1167 (21)             |
| Chakravarty et al 2016     | Medtronic CoreValve          | Concomitant and a priori           | 30-d mortality                        | 4/128 (3.1)               | 3/128 (2.3)               |
|                            | Edwards SAPIEN               |                                    | 30-d stroke                           | 1/128 (0.8)               | 2/128 (1.6)               |
|                            | Direct flow                  |                                    | 30-d MI                               | 0/128 (0)                 | 0/128 (0)                 |
|                            | Transfemoral/Trans-subclavian: 194/256 (75.8%) | | Procedural death                     | 0/128 (0)                 | 1/128 (0)                 |
|                            | Alternative access: 44/256 (17.2%) | | Procedural major or life-threatening bleeding | 2/128 (17) | 33/128 (26) |
|                            |                              |                                    | Procedural major vascular complications | 21/128 (16)               | 5/128 (3.9)               |
|                            |                              |                                    | Permanent pacemaker                   | 34/128 (27)               | 18/128 (14)               |
|                            |                              |                                    | AKI                                   | 6/128 (4.7)               | 7/128 (5.5)               |
|                            |                              |                                    | 1-y mortality                         | 12/128 (9.4)              | 13/128 (10)               |
|                            |                              |                                    | 1-y stroke                            | 1/128 (0.8)               | 3/128 (2.3)               |
|                            |                              |                                    | 1-y MI                                | 3/128 (2.3)               | 1/128 (0.8)               |
Coexisting Coronary Artery Disease

The prevalence of coexisting CAD was reported in both revascularized and nonrevascularized groups in 9 studies, and varied from 51.4% to 100%. Consequently, we conducted a subgroup analysis of clinical outcomes comparing studies reporting populations with 100% versus >50% (but <100%) of the patients presenting with CAD.

In subgroup analysis including studies in which the prevalence of CAD was 100%, the OR for 30-day mortality among patients who underwent PCI was 0.80 (95% CI, 0.28–2.27), whereas in studies in which the prevalence of CAD was >50% (but <100%), more patients who received PCI died (OR: 1.49; 95% CI, 1.12–1.98; \( P = 0.006 \); heterogeneity: \( P = 0.45, \ I^2 = 0\% \)). The overall difference showed significant effect estimates (OR: 1.42; 95% CI, 1.08–1.87; \( P = 0.01 \); heterogeneity: \( P = 0.63, \ I^2 = 20\% \)). No significant differences in effect estimates were observed in terms of cardiovascular (OR: 1.03; 95% CI, 0.35–2.99) and 1-year (OR: 1.05; 95% CI, 0.71–1.56) mortality rates. Similar effect estimates were found for the 2 strategies in the remaining analyzed variables (Figure 5).

Sensitivity analysis comparing random- versus fixed-effects models and excluding studies with no events in one of the treatment arms is shown in Table 6. The results suggest no differences in effect estimates between the 2 models or after excluding studies with no events in one of the treatment arms. Metaregression analysis was conducted to further investigate potential sources of clinical heterogeneity based on the prevalence of CAD. The results rule out a strong magnitude of the effect to influence any of the analyzed outcomes (Table 7).

Discussion

The results of this meta-analysis of 9 observational studies including 3858 patients show that PCI revascularization before (prior to and concomitant) TAVI may be associated with an increased risk of major vascular complications and 30-day mortality, although by 1 year, this association was no longer present. In addition, comparing TAVI with and without revascularization, there were no significant differences in rates of MI, bleeding, AKI/hemodialysis, or cerebrovascular accidents at 30 days. Notably, we found that the evidence basis consists of poor-quality studies confounded by selection bias, thus emphasizing the need for randomized controlled trials.
Table 5. Pooled Analysis for Adverse Outcomes With and Without Revascularization

| Outcome                        | Studies | Cumulative | %    | References | Studies | TAVI PCI | %    | References | Studies | TAVI Alone | %    | References |
|--------------------------------|---------|------------|------|------------|---------|----------|------|------------|---------|------------|------|------------|
| 30-d mortality                 | 18      | 368/5281   | 6.97 | 9–12, 23, 25, 26, 28, 31–37, 39–41 | 16      | 115/1441 | 7.98 | 9, 10, 12, 23, 25, 26, 31–37, 39–41 | 14      | 245/3757   | 6.52 | 9, 10, 12, 25, 26, 28, 31–35, 37, 39, 40 |
| 30-d cardiovascular mortality  | 5       | 52/1046    | 4.97 | 10, 12, 28, 32, 33 | 4       | 15/217   | 6.91 | 10, 12, 32, 33 | 5       | 37/829     | 4.46 | 10, 12, 28, 32, 33 |
| 1-y mortality                  | 9       | 545/2554   | 21.3 | 9, 27, 28, 32, 35, 37–39, 41 | 7       | 106/544  | 19.5 | 9, 27, 32, 35, 37–39, 41 | 8       | 439/2010   | 21.8 | 9, 27, 28, 32, 35, 37–39 |
| 2-y mortality                  | 2       | 258/449    | 57.5 | 32, 35     | 2       | 59/114   | 51.8 | 32, 35     | 2       | 199/335    | 59.4 | 32, 35     |
| Myocardial infarction          | 10      | 26/3109    | 0.84 | 10–12, 28, 31–33, 35, 39 | 8       | 5/482    | 1.0  | 10, 12, 31–33, 35, 39 | 8       | 13/1272    | 1.02 | 10, 12, 28, 31–33, 35, 39 |
| Major or life-threatening bleeding | 12    | 590/4074   | 14.5 | 10–12, 28, 31–34, 36, 39–41 | 10      | 131/1157 | 11.3 | 10, 12, 31–34, 36, 39–41 | 9       | 454/2834   | 16.0 | 10, 12, 28, 31–34, 39, 40 |
| Major vascular complications   | 11      | 227/3770   | 6.02 | 10, 12, 28, 31–34, 36, 39–41 | 10      | 98/1125  | 8.7  | 10, 12, 31–34, 36, 39–41 | 9       | 129/2645   | 4.9  | 10, 12, 28, 31–34, 39, 40 |
| Acute kidney injury            | 13      | 259/4288   | 6.04 | 10, 12, 22, 23, 28, 31–36, 39, 40 | 12      | 75/1222  | 6.13 | 10, 12, 22, 23, 31–36, 39, 40 | 10      | 184/3066   | 6.0  | 10, 12, 28, 31–35, 39, 40 |
| Stroke/transient ischemic attack | 11    | 41/1686    | 2.43 | 10–12, 22, 28, 31–34, 36, 39 | 9       | 12/530   | 2.26 | 10, 12, 22, 31–34, 36, 39 | 8       | 27/1073    | 2.5  | 10, 12, 28, 31–34, 39 |
| Pacemaker implantation         | 8       | 443/3382   | 13.1 | 10, 12, 31–34, 39, 40 | 8       | 120/959  | 12.5 | 10, 12, 31–34, 39, 40 | 8       | 323/2423   | 13.3 | 10, 12, 31–34, 39, 40 |

Values are expressed as the occurrence of an event/sample size. PCI indicates percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.
Assessing the Severity of CAD in Patients Undergoing TAVI

The optimal treatment of CAD in patients with TAVI remains to be elucidated. Although Dewey et al.\(^8\) showed that CAD is an independent predictor of early and midterm survival, this finding was not supported by other studies.\(^3,7,38,42,43\) In addition, Khawaja and colleagues\(^37\) showed that CAD was not a predictor of worse outcome, albeit in patients exhibiting a SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery) score >9. Chauhan and colleagues\(^43\) found no significant association between the SYNTAX or Duke Myocardial Jeopardy score with rates of their prespecified primary composite end point (all-cause mortality, major adverse cardiovascular and cerebrovascular event, and postoperative coronary revascularization) or secondary outcomes of the 30-day and 1-year composite end point. Moreover, the authors went further and questioned the role of coronary angiography as part of the TAVI workup.\(^43\) More recently, Paradis and colleagues\(^41\) showed that neither the severity of CAD nor the residual SYNTAX score after revascularization was associated with worse outcomes at 30 days and 1 year after TAVI.

As mentioned previously, the reported prevalence of CAD in the population undergoing TAVI varies depending on the definitions used to define significance (Table 1) and can be as high as 75%.\(^8-12\) The severity of CAD in AS patients has historically been assessed using angiography to further determine the need for revascularization; however, it is well known that functionally guided fractional flow reserve PCI strategies have shown improvements in patient outcome.\(^44\) Nonetheless, functional assessment of CAD in the presence of AS becomes difficult due to diffuse subendocardial ischemia leading to myocardial fibrosis as well as left ventricular remodeling and, often, severe hypertrophy.\(^45,46\) Consequently, coronary physiology is altered in patients with severe AS, and although the use of fractional flow reserve has not been validated for this group, fractional flow reserve has been performed safely in contemporaneous studies of patients with severe AS.\(^47-51\)

Coronary Revascularization and TAVI Outcomes

Our meta-analysis suggests that routine revascularization of patients with severe AS and concomitant CAD undergoing...
TAVI may be associated with an increased risk of major vascular complications and 30-day mortality, although the latter association was no longer present by 1 year. In this regard, Van Mieghem et al. have shown no significant difference between complete versus incomplete revascularization or for SYNTAX scores ≥8 versus <8. One of the theoretical arguments to support revascularization prior to TAVI is the anxiety that periprocedural MI might occur during...
the hypotension induced by rapid pacing for valvuloplasty or during valve delivery. Notably, Griese et al.\textsuperscript{33} showed that revascularization was associated with increased 30-day MI compared with TAVI alone; however, the study did not ascertain the prevalence of CAD in the TAVI-alone group or, indeed, the indication for PCI. As such, this study was excluded from our meta-analysis. Singh and colleagues\textsuperscript{40} showed worse 30-day outcomes when PCI was performed during the same admission, although, as above mentioned, this observation might have been driven by the difference in the reported prevalence of CAD between groups or by a questionable prevalence of CAD using \textit{International Classification of Diseases, Ninth Revision} coding. Higher 30-day mortality could also be associated with a higher preoperative risk profile, meaning that the PCI group may have been a higher risk cohort, translating into worse outcome; however, the authors did not report adjusting for preprocedural risk scoring. Importantly, our analysis shows that when both

Figure 3. Sensitivity analysis evaluating the cumulative risk of outcomes of patients undergoing transcatheter aortic valve implantation (TAVI) plus percutaneous coronary intervention (PCI) vs TAVI alone. AKI indicates acute kidney injury; CI, confidence interval; M-H, Mantel-Haenszel.
Figure 4. Meta-analyses evaluating outcomes between concomitant (same-setting) vs a priori revascularization of patients undergoing transcatheter aortic valve implantation plus percutaneous coronary intervention. CI indicates confidence interval; M-H, Mantel-Haenszel.
groups had 100% prevalence of CAD, there was no significant
difference in treatment effect estimates, likely due to a small
event rates (Figure 2A). Moreover, metaregression analysis
suggests that differences in the prevalence of CAD did not
fluence this outcome. Finally, the presence of multiple
comorbid conditions explains overall 30-day mortality, since
cardiovascular mortality was similar.

Timing for Revascularization: Concomitant Versus
A Priori Approach
Performing TAVI shortly after PCI mandates that the TAVI
procedure be performed while a patient is treated with dual
antiplatelet therapy, potentially increasing bleeding risk;
however, our analysis shows that major and minor bleeding
complications were not significantly different between pre-
TAVI PCI and isolated TAVI approaches. Studies that com-
pared concomitant and a priori revascularization approaches
found no significant differences for AKI and the need for hemodialysis.10,23,33 Interestingly, one would expect that the
likelihood of AKI increases with a concomitant approach,
owing to the larger contrast volumes and higher number of
catheter manipulations; however, as reported previously,
contrast amount per se was not associated with AKI during
TAVI procedures.52 In addition, in most studies that reported
the incidence of AKI, PCI was performed a priori rather than in

Figure 5. Subgroup analysis according to the prevalence of significant coronary artery disease (CAD) evaluating the cumulative risk of (A) 30-
day mortality, (B) cardiovascular mortality, (C) 1-year mortality, (D) myocardial infarction, (E) acute kidney injury and/or need for hemodialysis,
and (F) major and life-threatening bleeding of patients undergoing transcatheter aortic valve implantation (TAVI) plus percutaneous coronary
intervention (PCI) vs TAVI alone. CI indicates confidence interval; M-H, Mantel-Haenszel.
the same setting (1 study only; Figures 3 and 4). This finding likely reflects the influence of confounding variables because studies were not statistically powered to infer for AKI due to the low event rate.

The revised American guidelines on valvular heart disease have downgraded to class IIa (evidence C) the role of coronary revascularization at the time of surgical aortic valve replacement.3 Recommendations focused on TAVI13–15 while supporting the treatment of significant CAD do not provide suggestions about the timing of PCI relative to the TAVI procedure. Wenaweser et al10 reported on a combined approach separated into single-stage and staged procedures; later, van Rosendael et al36 found no differences when comparing revascularization within 30 days prior to TAVI, with PCI performed ≥30 days after TAVI. Thus, there are still very limited data available to inform an optimal strategy with respect to the timing of revascularization.

**Limitations**

The present study has several limitations. The main limitations are the small numbers of studies, patients, and events informing

| Outcome | Random Effects Odds Ratio (95% CI) | Fixed Effects Odds Ratio (95% CI) | Random-Effects Odds Ratio Excluding Studies With No Events in at Least 1 Arm |
|---------|----------------------------------|----------------------------------|--------------------------------------------------|
| 30-d mortality | 1.42 (1.08–1.87) | 1.37 (1.04–1.80) | 1.45 (1.10–1.91) |
| 100% CAD in TAVI alone group | 0.80 (0.28–2.27) | 0.80 (0.28–2.24) | 0.80 (0.28–2.27) |
| >50% CAD in TAVI alone group | 1.49 (1.12–1.98) | 1.43 (1.08–1.90) | 1.52 (1.14–2.02) |
| 1-y mortality | 1.05 (0.71–1.56) | 1.04 (0.70–1.54) | 1.05 (0.71–1.56) |
| 100% CAD in TAVI alone group | 0.99 (0.61–1.59) | 0.99 (0.61–1.59) | 0.99 (0.61–1.59) |
| >50% CAD in TAVI alone group | 1.14 (0.46–2.81) | 1.17 (0.58–2.36) | 1.14 (0.46–2.81) |
| Cardiovascular mortality | 1.03 (0.35–2.99) | 0.98 (0.34–2.81) | 1.03 (0.35–2.99) |
| >50% CAD in TAVI alone group | 1.03 (0.35–2.99) | 0.98 (0.34–2.81) | 1.03 (0.35–2.99) |
| Myocardial infarction | 0.86 (0.14–5.28) | 0.85 (0.14–5.22) | 0.76 (0.08–6.91) |
| 100% CAD in TAVI alone group | 0.76 (0.08–6.91) | 0.76 (0.08–6.91) | 0.76 (0.08–6.91) |
| >50% CAD in TAVI alone group | 1.10 (0.04–27.38) | 1.10 (0.04–27.38) | Not estimable |
| Major or life-threatening bleeding | 0.82 (0.54–1.26) | 0.72 (0.55–0.94) | 0.86 (0.53–1.39) |
| 100% CAD in TAVI alone group | 2.78 (0.25–31.37) | 2.78 (0.25–31.37) | 2.78 (0.25–31.37) |
| >50% CAD in TAVI alone group | 0.79 (0.51–1.20) | 0.70 (0.54–0.92) | 0.82 (0.50–1.33) |
| Major vascular or access site complication | 1.86 (1.33–2.60) | 1.78 (1.31–2.43) | 1.86 (1.33–2.60) |
| 100% CAD in TAVI alone group | 2.09 (0.34–12.94) | 2.04 (0.35–11.84) | 2.09 (0.34–12.94) |
| >50% CAD in TAVI alone group | 1.85 (1.32–2.60) | 1.77 (1.29–2.43) | 1.85 (1.32–2.60) |
| Acute kidney injury and/or dialysis | 0.89 (0.42–1.88) | 0.88 (0.61–1.28) | 0.95 (0.43–2.08) |
| 100% CAD in TAVI alone group | 1.17 (0.62–2.23) | 1.17 (0.62–2.23) | 1.17 (0.62–2.23) |
| >50% CAD in TAVI alone group | 0.77 (0.26–2.28) | 0.77 (0.49–1.22) | 0.87 (0.27–2.82) |
| Stroke | 1.07 (0.38–2.97) | 1.00 (0.40–2.49) | 1.07 (0.38–2.97) |
| 100% CAD in TAVI alone group | 1.37 (0.19–10.03) | 1.37 (0.19–10.03) | 1.37 (0.19–10.03) |
| >50% CAD in TAVI alone group | 1.02 (0.24–4.41) | 0.92 (0.32–2.60) | 1.02 (0.24–4.41) |
| Pacemaker implantation | 0.85 (0.49–1.46) | 0.69 (0.52–0.90) | 0.85 (0.49–1.46) |
| 100% CAD in TAVI alone group | 0.75 (0.34–1.64) | 0.75 (0.34–1.64) | 0.75 (0.34–1.64) |
| >50% CAD in TAVI alone group | 0.88 (0.43–1.81) | 0.68 (0.51–0.91) | 0.88 (0.43–1.81) |
| Combined safety | 0.81 (0.48–1.37) | 0.81 (0.48–1.36) | 0.81 (0.48–1.37) |
| 100% CAD in TAVI alone group | 1.39 (0.38–5.04) | 1.39 (0.38–5.04) | 1.39 (0.38–5.04) |
| >50% CAD in TAVI alone group | 0.73 (0.41–1.29) | 0.73 (0.41–1.29) | 0.73 (0.41–1.29) |

CAD indicates coronary artery disease; CI, confidence interval; TAVI, transcatheter aortic valve implantation.
Conclusion

Our findings suggest that revascularization before or during TAVI confers no clinical advantage with respect to several patient-important clinical outcomes and may be associated with an increased risk of major vascular complications and 30-day mortality. These data, however, are based on observational studies including initial high-risk cohorts of patients with limited follow-up and may not be applicable to lower risk cohorts with greater life expectancy. Randomized controlled trials are needed to determine the role of routine revascularization in patients with significant CAD undergoing TAVI. Meanwhile, in the absence of definitive evidence, careful evaluation of patients on an individual basis by a dedicated heart team is of paramount importance to identify patients, such as those with significant CAD affecting proximal main epicardial vessels, for whom the benefits of elective revascularization are balanced against the potential risks.

Sources of Funding

This study was supported in part by a Program of Experimental Medicine (POEM) Research Award, Department of Medicine, Western University, London, Ontario, Canada.

Disclosures

None.

References

1. Rapp AH, Hillis LD, Lange RA, Cigarroa JE. Prevalence of coronary artery disease in patients with aortic stenosis with and without angina pectoris. Am J Cardiol. 2001;87:1216–1217.

2. Goel SS, Agarwal S, Tuzcu EM, Ellis SG, Svensson LG, Zaman T, Bajaj N, Joseph L, Patel NS, Aksoy O, Stewart WJ, Griffin BP, Kapadia SR. Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement. Circulation. 2012;125:1005–1013.

3. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin III JP, Guyton RA, O’Gara PT, Ruiz CE, Skubas NJ, Sorajja P, Sundt III TM, Thomas JD. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2438–2488.

4. Vahanian A, Andreotti F, Anter M, Alfonso F, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, de Boer MA, Evangelista A, Falk V, Farkouh ME, Fuster V, Gersh BJ, Gillebert TC, Grines CL, Halvorsen S, Herold BC, Hirzel CM, Kaye G, Kappetein AP, Karp LA, Kaul S, Kuck KH, Lang CC, Leesar M, Leon MB, Lindner M, Lip GY, Lipshutz SC, Lock JE, Louvard Y, Lopez-Sendon J, O’Gara PT, Ormiston JA, Perri RM, Piazza N, Radtke M, Roelandt JR, Roelandt JT, Rolf B, Rosano GM, Rutten FH, Samady H, Sarno F, Schuler G, Schuster M, Sechtem U, Seegers H, Serruys PW, Sirol SK, Skwira D, Spaan JA, Stankovic G, Stankovic I, Tcheng JE, Vahanian A. Guidelines on the management of valvular heart disease (version 2012). Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology and (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33:2451–2496.

5. Li Z, Anderson I, Amsterness EA, Young JN, Parker I, Armstrong EJ. Effect of coronary artery disease extent on contemporary outcomes of combined aortic valve replacement and coronary artery bypass graft surgery. Ann Thorac Surg. 2013;96:2075–2082.

6. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, Joyce LD, Burkhart HM, Pochettino A, Poouchettino A, Li Z, Frye BJ, Schaff HV. The prognostic impact of concomitant coronary artery bypass grafting during aortic valve surgery: implications for revascularization in the transcatheter era. J Thorac Cardiovasc Surg. 2015;149:451–460.

7. Dell’Amore A, Aquino TM, Pagliaro M, Lamarr M, Zussa C. Aortic valve replacement with and without combined coronary bypass grafts in very elderly patients: early and long-term results. Eur J Cardiothorac Surg. 2012;41:491–498.

8. Dewey TM, Brown DL, Herbert MA, Colica D, Smith CR, Leon MB, Svensson LG, Tuzcu M, Webb JG, Cribier A, Mack MJ. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann Thorac Surg. 2010;89:758–767.

9. Masson JB, Lee M, Boone RH, Al Ali A, Al Bugami S, Hamburger J, John Mancini GB, Ye J, Cheung A, Humphries KH, Wood D, Nietlispach F, Webb JG. Impact of coronary artery disease on outcomes after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2010;76:165–173.

10. Wenaweser P, Pilgrim T, Guerios E, Stortecky S, Huber C, Khattab AA, Kadner A, Buellesfeld L, Gloorak S, Meier B, Carrel T, Windecker S. Impact of concomitant coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. EuroIntervention. 2011;7:541–548.

11. Gautier M, Pepin M, Himbert D, Ducrocq G, Ung B, Dilly MP, Attias D, Nafat P, Vahanian A. Impact of coronary artery disease on indications for transcatheter aortic valve implantation and on procedural outcomes. EuroIntervention. 2011;7:549–555.
12. Abdel-Wahab M, Mostafa AE, Geist V, Stocker B, Gordan K, Merten C, Richard T, Toelig R, Richard G. Comparison of outcomes in patients having isolated transcatheter aortic valve implantation concomitant with preprocedural percutaneous coronary intervention. Am J Cardiol. 2012;109:581–586.

13. Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, De Jaegere P, Fournil G, Kappetein AP, Kovac J, Ludgate S, Maisano F, Moat N, Mohr F, Nataf P, Pierard L, Pomar JL, Schofer J, Tornos P, Tuzcu M, van Hout B, Wabbes M, Wijns W, Walther T; European Association of Cardio-Thoracic, European Society of C and European Association of Percutaneous Cardiovascular Inter I. Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2008;29:1463–1470.

14. Goel SS, Ige M, Tuzcu EM, Ellis SG, Stewart WJ, Svensson LG, Lyle BW, Kapadia SR. Severe aortic stenosis and coronary artery disease-implications for management in the transcatheter aortic valve replacement era: a comprehensive review. J Am Coll Cardiol. 2013;62:1–10.

15. Ramee S, Anwaruddin S, Kumar G, Plana RN, Babaliaros V, Rab T, Klein LW; Aortic Stenosis AUCWG and Interventional Section of the Leadership Council of the American College of C. The rationale for performance of coronary angiography and stenting before transcatheter aortic valve replacement: from the Interventional Section Leadership Council of the American College of Cardiology. JACC Cardiovasc Interv. 2016;9:2371–2375.

16. Kappetein AP, Head SJ, Genermuc P, Plasia N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van ES GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Valgimigli M, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint de EAPCI consensus document. J Am Coll Cardiol. 2012;60:1438–1454.

17. Moher D, Liberati A, Tetzlaff J, Altman DG; Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264–269.

18. Wells G, Shea B, O’Connell P, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute; 2011. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed September 30, 2016.

19. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.

20. Thabane L, Mbuagbaw L, Zhang S, Samaan Z, Marcucci M, Ye C, Thabane M, Mccarthy M, Denis B, Kosa D, Borg Debono V, Dillenburg R, Fruci V, Bawor M, Lee J, Wells G, Goldsmith CH. A tutorial on sensitivity analyses in clinical trials: the what, why and how. BMC Med Res Methodol. 2013:13:92.

21. Gagnier JJ, Morgenstern H, Altman DG, Berlowitz D. Research methodology for imaging studies: a simultaneous approach. Eur Heart J. 2013;34:P5392.

22. Nowakowski K, Poon K, Savage M, Lefebvre T, Lindman BR, Hariri B, Patel J, Takahashi N, Matar G, Mirocha J, Cheng W, Tuzcu ME, Sierwer H, Rodés-Cabau J, Colombo A, Finkelstein A, Fajadet J, Makkar RK. Outcomes in patients with transcatheter aortic valve implantation and left main stenting: the TAVR-LM registry. J Am Coll Cardiol. 2016;67:951–960.

23. Chakravarty T, Sharma R, Abramowitz Y, Kapadia S, Litvack J, Hlaihali H, Podder KL, Giustino G, Ribeiro HB, Tchetchet D, Montel B, Testa L, Tarantini G, Facchin M, Leteved F, Lindean BR, Harris, Patel J, Takahashi N, Matar G, Mirocha J, Cheng W, Tuzcu ME, Sierwer H, Rodés-Cabau J, Colombo A, Finkelstein A, Fajadet J, Makkar RK. Outcomes in patients with transcatheter aortic valve implantation left main stenting: the TAVR-LM registry. J Am Coll Cardiol. 2016;67:951–960.

24. Singh V, Rodriguez A, Thakkar B, Patel N, Ghatak A, Badheka A, Alfonso C, de Mattos-Azevedo S, Santiago MC. Comparison of outcomes of transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (AVR): a systematic review and meta-analysis. JACC Cardiovasc Interv. 2017;10:653–660.

25. Hirschberg CR, Bandyk DF, Shlipak MG, Metzelder DM, Yeh SJ, Brown RH, Stinson EB, Lytle BW. Prognostic value of coronary artery disease in patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2015;8:1234–1240.

26. Kodali S, Mack MJ, Mehran R, Rodes-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definition for transcatheter aortic valve implantation: the Valve Academic Research Consortium–2 consensus document. J Am Coll Cardiol. 2012;60:1438–1454.

27. Codner P, Assali A, Dvir D, Vaknin-Assa H, Porat E, Sharipova Y, Kupershmidt M, Bental T, Battler A, Magid A, Kornowski R. Two-year outcomes for patients with severe aortic stenosis and coronary artery disease treated with transcatheter aortic valve implantation: patient characteristics and influence on outcome. Eur Heart J. 2013;34:5392. Accessed September 30, 2016.

28. Gasparetto V, Fraccaro C, Tarantini G, Buja P, Ondrofi A, Yzeirej A, Pittarello D, Isabella G, Gerosa G, Iliescu S, Napadano M. Safety and effectiveness of a selective strategy for coronary artery revascularization before transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2013;81:376–383.
perfusion reserve in severe aortic stenosis. *JACC Cardiovasc Imaging*. 2012;5:182–189.

46. Pijls NH, Sels JW. Functional measurement of coronary stenosis. *J Am Coll Cardiol*. 2012;59:1045–1057.

47. Camuglia AC, Syed J, Garg P, Kiani B, Chu MW, Jones PM, Bainbridge D, Teefy PJ. Invasively assessed coronary flow dynamics improve following relief of aortic stenosis with transcatheter aortic valve implantation. *J Am Coll Cardiol*. 2014;63:1808–1809.

48. Wiegerinck EM, van de Hoef TP, Rolandi MC, Yong Z, van Kesteren F, Koch KT, Vis MM, de Mol BA, Piek JJ, Baan J. Impact of aortic valve stenosis on coronary hemodynamics and the instantaneous effect of transcatheter aortic valve implantation. *Circ Cardiovasc Interv*. 2015;8:e002443.

49. Stahli BE, Maier W, Corti R, Luscher TF, Altwegg LA. Fractional flow reserve evaluation in patients considered for transfemoral transcatheter aortic valve implantation: a case series. *Cardiology*. 2012;123:234–239.

50. Di Gioia G, Pellicano M, Toth GG, Casselman F, Adjedj J, Van Praet F, Ferrara A, Stockman B, Degrieck I, Bartunek J, Trimarco B, Wijns W, De Bruyne B, Barbato E. Fractional flow reserve-guided revascularization in patients with aortic stenosis. *Am J Cardiol*. 2016;117:1511–1515.

51. Stanojevic D, Gunasekaran P, Tadros P, Wiley M, Earnest M, Mehta A, Lippmann M, Levine M, Dawn B, Gupta K. Intravenous adenosine infusion is safe and well tolerated during coronary fractional flow reserve assessment in elderly patients with severe aortic stenosis. *J Invasive Cardiol*. 2016;28:357–361.

52. Bagur R, Webb JC, Nietlispach F, Dumont E, De Larochelliere R, Doyle D, Masson JB, Gutierrez MJ, Clavel MA, Bertrand OF, Pibarot P, Rodes-Cabau J. Acute kidney injury following transcatheter aortic valve implantation: predictive factors, prognostic value, and comparison with surgical aortic valve replacement. *Eur Heart J*. 2010;31:865–874.

53. Khawaja MZ, Wang D, Pocock S, Redwood SR, Thomas MR. The percutaneous coronary intervention prior to transcatheter aortic valve implantation (ACTIVATION) trial: study protocol for a randomized controlled trial. *Trials*. 2014;15:300.
Transcatheter Aortic Valve Implantation With or Without Percutaneous Coronary Artery Revascularization Strategy: A Systematic Review and Meta–Analysis
Rafail A. Kotronias, Chun Shing Kwok, Sudhakar George, Davide Capodanno, Peter F. Ludman, Jonathan N. Townend, Sagar N. Doshi, Saib S. Khogali, Philippe Généreux, Howard C. Herrmann, Mamas A. Mamas and Rodrigo Bagur

*J Am Heart Assoc.* 2017;6:e005960; originally published June 27, 2017; doi: 10.1161/JAHA.117.005960

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/6/6/e005960

Subscriptions, Permissions, and Reprints: The *Journal of the American Heart Association* is an online only Open Access publication. Visit the Journal at  http://jaha.ahajournals.org for more information.